Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background The combination of antivirals and monoclonal antibodies (mAbs) in the first phase of COVID-19 has demonstrated to reduce time to viral clearance, but the superiority of combination compared to antiviral monotherapy is still debated.Research design and methods In an observational, prospective study, we enrolled immunocompromised outpatients with mild-to-moderate COVID-19 treated with one antiviral monotherapy within 7 days from symptoms onset, with or without sotrovimab from January 1, 2024 to October 31, 2024, and we compared them to an identical cohort of patients treated with a combination of one antiviral and sotrovimab, from May 1, 2023 to December 30, 2023. 1st of May 2023 and 31st of October 2024. Sotrovimab administered until the end of October 2023 was considered to be presumably effective against the circulating viral variants, based on virological reports.Results We enrolled considered 98 patients treated with nirmatrelvir/ritonavir or remdesivir. Sotrovimab was co-administered in 50/98 cases. All the patients cleared SARS-CoV-2 infection within a median of 17 (IQR 10–22) days. At the multivariate Cox regression analysis, therapy administration within 3 days from symptoms’ onset (aHR 1.68; p = 0.031) and presumed sotrovimab effectiveness (aHR 1.75; p = 0.02) were found to be independent factors associated with for shorter time to viral clearance.Conclusions The timing of administration of early antiviral therapy is crucial to reduce SARS-CoV-2 infection duration in immunocompromised patients and the combination with a mAb is associated with earlier viral clearance, as long asmAb is chosen among those effective against circulating variants.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study
- Date Crossref
- 05/09/2025
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Naples Federico II pays non établi dans la noticeUniversité ou école supérieure
-
Federico II University Hospital pays non établi dans la noticeÉtablissement de santé
-
Ospedale Antonio Cardarelli pays non établi dans la noticeÉtablissement de santé
-
Fatebenefratelli Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Naples “Federico II” Department of Clinical Medicine and Surgery pays non établi dans la noticeUniversité ou école supérieure
-
University of Naples "Federico II" Department of Clinical Medicine and Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Cardarelli Hospital Hematology Unit pays non établi dans la noticeÉtablissement de santé
University of Naples Federico II, Federico II University Hospital et Ospedale Antonio Cardarelli, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.